Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Dasatinib is a potent oral tyrosine kinase inhibitor which targets several kinases, including the SRC family kinases. SRC family kinases have been implicated in androgen therapy resistance that often develops in metastatic castration-resistant prostate cancer (mCRPC), which drives the need for non-a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Araujo, John C, Trudel, Geralyn C, Paliwal, Prashni
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2013
Teme:
Case Report
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3601649/
https://ncbi.nlm.nih.gov/pubmed/23516140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S41667
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki